Items where authors include "Silva, S."

Article

Sgrò, A., Blanco-Colino, R., Brindl, N. et al. (5363 more authors) (2025) Extended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study. British Journal of Surgery, 112 (3). znaf005. ISSN 0007-1323

Schumacher, A.E., Kyu, H.H., Aali, A. et al. (1833 more authors) (2024) Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. The Lancet, 403 (10440). pp. 1989-2056. ISSN 0140-6736

Bhattacharjee, N.V., Schumacher, A.E., Aali, A. et al. (1403 more authors) (2024) Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. The Lancet, 403 (10440). pp. 2057-2099. ISSN 0140-6736

Ferrari, A.J., Santomauro, D.F., Aali, A. et al. (1325 more authors) (2024) Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet, 403 (10440). pp. 2133-2161. ISSN 0140-6736

Vollset, S.E., Ababneh, H.S., Abate, Y.H. et al. (1417 more authors) (2024) Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021. The Lancet, 403 (10440). pp. 2204-2256. ISSN 0140-6736

Brauer, M., Roth, G.A., Aravkin, A.Y. et al. (1792 more authors) (2024) Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet, 403 (10440). pp. 2162-2203. ISSN 0140-6736

Naghavi, M., Ong, K.L., Aali, A. et al. (1997 more authors) (2024) Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet, 403 (10440). pp. 2100-2132. ISSN 0140-6736

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Terrado, M., Marcos, R., González-Reviriego, N. et al. (12 more authors) (2023) Co-production pathway of an end-to-end climate service for improved decision-making in the wine sector. Climate Services, 30. 100347. ISSN 2405-8807

Bergamino, M.A. orcid.org/0000-0002-1091-2711, López-Knowles, E. orcid.org/0000-0002-0893-3361, Morani, G. orcid.org/0000-0002-6385-3137 et al. (173 more authors) (2022) HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. eBioMedicine, 83. 104205. ISSN 2352-3964

Coombes, R.C., Tovey, H., Kilburn, L. et al. (230 more authors) (2021) Effect of celecoxib vs placebo as adjuvant therapy on disease-free survival among patients with breast cancer. JAMA Oncology, 7 (9). p. 1291. ISSN 2374-2437

Coen, O., Corrie, P., Marshall, H. et al. (17 more authors) (2021) The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 21 (1). 761. ISSN 1471-2407

Silva, S., Danson, S., Teare, M.D. et al. (12 more authors) (2018) Genome-wide analysis of circulating cell-free DNA copy number detects active melanoma and predicts survival. Clinical Chemistry, 64 (9). pp. 1338-1346. ISSN 0009-9147

Proceedings Paper

Danson, S., Collinson, M., Plummer, E.R. et al. (17 more authors) (2025) Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial. In: Journal of Clinical Oncology. 2025 ASCO Annual Meeting II, 30 May - 03 Jun 2025, Chicago, USA. American Society of Clinical Oncology (ASCO) .